MedTrace Logo

Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer

NCT06115174 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2023-11-02

No results posted yet for this study

Summary

The aim of this work is to assess the antitumor effect of Pentoxiphylline in patients with metastatic colorectal cancer receiving stomatal chemotherapy ± targeted therapy.

Conditions

  • Metastatic Colorectal Carcinoma

Interventions

DRUG

Pentoxifylline

Pentoxifylline (PTX) is a methylxanthine derivative that is commercially available in the name of Trental. It is currently used for management of peripheral vascular diseases. Its postulated mechanism of action is thought to be mediated through reducing blood viscosity and enhancing RBCs flexibility. However, it has been shown that PTX also may potentially be used in the anticancer therapy \[15\]. The studies demonstrated the potential effects of pentoxifylline on angiogenesis inhibition. It can affect the release and function of some predominantly proangiogenic vascular endothelial growth factors. Specifically, the release of the VEGF family of pro-angiogenesis factors (notably VEGF-A and VEGF-C) \[16\]. Furthermore, the mechanism by which pentoxifylline inhibits angiogenesis may be through the inhibition of activation of STAT3 which contributes to tumor cell survival by regulating the expression of metastatic genes, MMPs, serine protease uPA and potent angiogenic genes \[17\].

RADIATION

FOLFOX

(leucovorin, fluorouracil, oxaliplatin)

RADIATION

XELOX

(oxaliplatin + capecitabine)

DRUG

Monoclonal antibodies (target therapy)

target therapy (Bevacizumab).

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Tarek Mohammed, Professor · Tanta University

  • Dalia Refaat, Assistant Professor · Tanta University

  • Sherif Refaat, Lecturer · Oncology Centre - Faculty of Medicine - Mansoura University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-01
Primary Completion
2024-11-01
Completion
2024-12-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06115174 on ClinicalTrials.gov